Your session is about to expire
← Back to Search
Other
Respirogen Micro-Oxygen for Hypoxia
Phase < 1
Waitlist Available
Led By Chris Bell, PhD
Research Sponsored by Christopher Bell
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up randomized crossover, visits separated by a minimum 7 days and maxim 14 days
Awards & highlights
Study Summary
This study is evaluating whether a new oxygen delivery method may help improve oxygen levels in individuals who are experiencing low oxygen levels.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ randomized crossover, visits separated by a minimum 7 days and maxim 14 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~randomized crossover, visits separated by a minimum 7 days and maxim 14 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Increases Oxygen saturation (SpO2) with RMO
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Low Oxygen Visits with Respirogen Micro-OxygenExperimental Treatment1 Intervention
During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
Group II: Low Oxygen Visits without Respirogen Micro-OxygenActive Control1 Intervention
During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
Find a Location
Who is running the clinical trial?
Christopher BellLead Sponsor
8 Previous Clinical Trials
213 Total Patients Enrolled
Respirogen Inc.UNKNOWN
Chris Bell, PhDPrincipal InvestigatorCSU
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger